Jason Hoitt - 18 Jan 2022 Form 4 Insider Report for Provention Bio, Inc.

Role
Chief Commercial Officer
Signature
/s/ Thierry Chauche, as attorney-in-fact
Issuer symbol
N/A
Transactions as of
18 Jan 2022
Net transactions value
$0
Form type
4
Filing time
20 Jan 2022, 16:20:09 UTC
Previous filing
14 May 2021
Next filing
09 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRVB Stock Option (right to buy) Award $0 +145,000 $0.000000 145,000 18 Jan 2022 Common Stock, par value $0.0001 145,000 $4.39 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest and become exercisable as to 25% on the one-year anniversary of the grant date (January 18, 2023) and the remaining 75% will vest and become exercisable monthly over 36 months such that the options are fully vested and exercisable on the four-year anniversary of the grant date (January 18, 2026).
F2 The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan.

Remarks:

Exhibit 24.1 - Power of Attorney